Edwards Lifesciences Co. (NYSE:EW) Shares Sold by Baillie Gifford & Co.

Baillie Gifford & Co. trimmed its position in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) by 8.3% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 403,958 shares of the medical research company's stock after selling 36,443 shares during the quarter. Baillie Gifford & Co. owned 0.07% of Edwards Lifesciences worth $30,802,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also bought and sold shares of the company. Moneta Group Investment Advisors LLC grew its position in Edwards Lifesciences by 104,971.3% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 15,399,249 shares of the medical research company's stock valued at $1,148,938,000 after acquiring an additional 15,384,593 shares during the last quarter. Norges Bank purchased a new stake in shares of Edwards Lifesciences during the fourth quarter valued at $658,390,000. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST grew its holdings in shares of Edwards Lifesciences by 440.0% in the third quarter. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST now owns 3,510,000 shares of the medical research company's stock worth $243,173,000 after purchasing an additional 2,860,000 shares during the last quarter. AustralianSuper Pty Ltd purchased a new position in Edwards Lifesciences in the 4th quarter worth about $168,519,000. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main lifted its holdings in Edwards Lifesciences by 655.9% during the 4th quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 2,325,457 shares of the medical research company's stock valued at $173,502,000 after buying an additional 2,017,801 shares in the last quarter. Institutional investors own 79.46% of the company's stock.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 10,000 shares of the business's stock in a transaction on Friday, January 12th. The shares were sold at an average price of $75.67, for a total value of $756,700.00. Following the completion of the transaction, the vice president now owns 39,503 shares in the company, valued at $2,989,192.01. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 11,000 shares of the stock in a transaction that occurred on Tuesday, February 13th. The shares were sold at an average price of $85.83, for a total value of $944,130.00. Following the sale, the vice president now directly owns 39,503 shares of the company's stock, valued at approximately $3,390,542.49. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, VP Donald E. Bobo, Jr. sold 10,000 shares of Edwards Lifesciences stock in a transaction on Friday, January 12th. The stock was sold at an average price of $75.67, for a total transaction of $756,700.00. Following the sale, the vice president now directly owns 39,503 shares of the company's stock, valued at $2,989,192.01. The disclosure for this sale can be found here. In the last three months, insiders have sold 204,004 shares of company stock valued at $17,922,954. 1.27% of the stock is owned by corporate insiders.

Edwards Lifesciences Stock Performance

Shares of NYSE:EW traded down $0.10 during trading on Thursday, hitting $91.41. 2,446,476 shares of the stock traded hands, compared to its average volume of 3,931,911. The company has a fifty day moving average price of $89.93 and a two-hundred day moving average price of $77.54. Edwards Lifesciences Co. has a 52-week low of $60.57 and a 52-week high of $96.12. The company has a market cap of $55.02 billion, a price-to-earnings ratio of 39.74, a P/E/G ratio of 4.57 and a beta of 1.05. The company has a quick ratio of 2.40, a current ratio of 3.38 and a debt-to-equity ratio of 0.09.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its quarterly earnings results on Tuesday, February 6th. The medical research company reported $0.64 earnings per share for the quarter, meeting the consensus estimate of $0.64. The firm had revenue of $1.53 billion during the quarter, compared to analyst estimates of $1.50 billion. Edwards Lifesciences had a return on equity of 23.56% and a net margin of 23.35%. Edwards Lifesciences's revenue for the quarter was up 13.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.64 EPS. As a group, equities analysts predict that Edwards Lifesciences Co. will post 2.76 EPS for the current year.

Wall Street Analyst Weigh In

EW has been the subject of a number of research analyst reports. Stifel Nicolaus lifted their target price on Edwards Lifesciences from $70.00 to $83.00 and gave the company a "hold" rating in a research report on Wednesday, February 7th. Truist Financial raised their target price on shares of Edwards Lifesciences from $78.00 to $84.00 and gave the company a "buy" rating in a research report on Friday, December 22nd. Evercore ISI raised their price target on shares of Edwards Lifesciences from $86.00 to $92.00 and gave the company an "in-line" rating in a report on Thursday, April 4th. Bank of America raised Edwards Lifesciences from a "neutral" rating to a "buy" rating in a research report on Thursday, March 7th. Finally, OTR Global raised Edwards Lifesciences from a "mixed" rating to a "positive" rating in a research report on Tuesday, March 26th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $91.33.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.